| Document |
Document Title |
|
WO/2020/188478A1 |
The invention relates to rigidified pentadentate chelating agents of Formulae (I) and (II), which are useful for the [Al18F]2+ labelling of biomolecules. The chelating agents of the invention are used to form coordination complexes with ...
|
|
WO/2020/191365A1 |
Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mamm...
|
|
WO/2020/188318A1 |
Process for preparation of polymeric nanoparticles that chelate radioactive isotopes and have their surface modified with specific molecules targeting PSMA receptor on the surface of cancer cells, with a targeting agent modified by a lin...
|
|
WO/2020/188023A1 |
The invention relates to the diagnostic uses of a conjugate comprising Omomyc or a functionally equivalent variant thereof and a detectable label for detecting lung cancer by pulmonary administration of the conjugate. The invention also ...
|
|
WO/2020/186328A1 |
A chelating agent having the general formula (I) is provided (I) Metal chelates and constructs for carrying out targeted radionuclide therapy incorporating such chelating agents are provided. Methods of making and using the chelating age...
|
|
WO/2020/185897A1 |
A method of treating CNS tumors such as gliomas is provided comprising delivering a β-emitting radionuclide containing composition to the tumor via the cerebral vasculature.
|
|
WO/2020/178795A1 |
The present disclosure relates to [18F]-labeled benzothiazole derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in ...
|
|
WO/2020/180756A1 |
Among the various aspects of the present disclosure is the provision of compositions of isotope-ligand complexes, methods of use thereof, and methods of chelating isotopes. The present disclosure also provides for methods for modulating ...
|
|
WO/2020/174963A1 |
Provided is an α-synuclein aggregate binding agent having high selectivity for binding to α-synuclein aggregates. An α-synuclein aggregate binding agent containing a compound represented by formula (I), a salt acceptable as a pharma...
|
|
WO/2020/176794A1 |
Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.
|
|
WO/2020/169538A1 |
The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate...
|
|
WO/2020/169537A1 |
The present invention relates to combinations of at least two components, component A and component B, component A being a PD-1/PD-L1 inhibitor, and component B being a targeted thorium conjugate. Another aspect of the present invention ...
|
|
WO/2020/165420A1 |
The present invention relates to a compound of formula (1), and to a complex comprising said compound and a radionuclide, and to the respective pharmaceutical composition, the compound having the following structure or a pharmaceutically...
|
|
WO/2020/165409A1 |
In particular, the present invention relates to a PSMA binding ligand comprising an oligosaccharide building block which comprises a bond being cleavable by alpha-amylase. Typically, this PSMA binding ligand further comprises a PSMA bind...
|
|
WO/2019/143016A9 |
The present invention obtains, by PET, images of neurogenic inflammation, cerebral apoplexy and tumors, which are associated with new translocator protein overexpression, through a fluorine-18-labeled translocator protein overexpression-...
|
|
WO/2020/163614A1 |
The discovery that contrast in blood vessels varies at cardiac frequency in magnitude and phase enables a set of processes for increasing the signal to noise ratio or equivalently the informational content of an angiogram. In this invent...
|
|
WO/2020/072784A9 |
A composition comprises a conjugate of the formula targeting component-linker-imaging component. In an embodiment, the targeting component is a VLA-4 antagonist. In an embodiment, the targeting component is a LFA-1 antagonist. In an embo...
|
|
WO/2020/156507A1 |
Novel single domain antibodies and antibody fragments specifically binding to PD-L1, and compositions comprising said antibodies or antibody fragments are provided. Nucleic acid encoding said antibodies or antibody fragments, host cells ...
|
|
WO/2020/157184A1 |
The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety ...
|
|
WO/2020/156345A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to a PSMA inhibitor, a compound and an application. The PSMA inhibitor having a novel core structure as provided by the present invention has v...
|
|
WO/2020/157128A1 |
A ligand-SiFA conjugate compound represented by formula (1) wherein: RL is a ligand moiety which is capable of binding to prostate-specific membrane antigen (PSMA); RSiFA is a silicon-fluoride acceptor (SiFA) moiety which can be labeled ...
|
|
WO/2020/157177A1 |
The present invention relates to a compound according to formula (V): or a pharmaceutically acceptable salt thereof, optionally containing a chelated radioactive cation and wherein F is optionally 18F.
|
|
WO/2020/159080A1 |
The present invention provides a photo-crosslinkable hydrogel and a preparation method therefor. The hydrogel may comprise a radioactive isotope-labeled photo-crosslinkable compound or a pharmaceutically acceptable salt thereof and can b...
|
|
WO/2020/154110A1 |
The present disclosure relates to novel compositions comprising hydrophilic polymer-conjugated bilirubin-coated radio-luminescent particle or particle aggregates, and methods to make and use the novel compositions. A specific novel PEG-B...
|
|
WO/2020/154733A1 |
Compositions and methods are disclosed for assessing macrophage involvement in the inflammation of one or more joints of a subject. In certain aspects, the disclosed method includes the steps of administering to the subject a composition...
|
|
WO/2020/153940A1 |
Antibodies and antigen binding fragments thereof that specifically recognize and bind an epitope of elastin that is exposed and accessible in degraded elastic fiber are described. The antibodies and/or antigen binding fragments can be op...
|
|
WO/2020/152426A1 |
The present invention concerns the field of medical devices, more particularly devices for jointly extracting, within an organism, at least one metal cation and at least one target molecule. In order to do this, the device comprises: a) ...
|
|
WO/2020/150617A2 |
|
|
WO/2020/148154A1 |
The invention concerns a compound according to following formula, wherein R1 is an F or an I residue.
|
|
WO/2020/146515A1 |
The present application provides picolinamide compounds that can be used as allosteric positron emission tomography ("PET") imaging probes. Methods of using these compounds for treating a neurodegenerative disease are also provided.
|
|
WO/2020/144586A1 |
Radio-drug suitable for performing radio-guided surgery, imaging diagnostics, radio-metabolic therapy.
|
|
WO/2020/145228A1 |
[Problem] To provide a complex comprising a ligand, a spacer, and a peptide linker useful in internal diagnostics and internal radiation therapy, that uses an anti-human CEACAM5 antibody Fab fragment the binding activity of which is not ...
|
|
WO/2020/142847A1 |
Monovalent antibodies such as nanobodies that are specific for galectin-7 are described. These monovalent antibodies are able to interfere with the dimerization of galectin-7, and thus may be used for the treatment of diseases associated...
|
|
WO/2020/145977A1 |
The present invention provides a dosage-specific treatment for lung and neuroendocrine tumors with a targeted radiotherapeutic somatostatin analogue, Re-P2045 in combination with topotecan or a histone deacetylase inhibitor. Patients are...
|
|
WO/2020/143720A1 |
The present invention provides a multi-target fusion protein, used for blocking vascular endothelial growth and activating T cells, comprising (i) a vascular endothelial growth repression domain; (ii) an Fc region of immunoglobulin; and ...
|
|
WO/2020/145227A1 |
[Problem] To provide a complex comprising a ligand, spacer, and peptide linker useful in internal diagnostics and internal radiation therapy that uses an anti-human MUC1 antibody Fab fragment the binding activity of which is not weakened...
|
|
WO/2020/145776A1 |
The present invention relates to a composition for targeting medullary thyroid cancer, the composition comprising a diagnostic radionucleotide-labeled ligand of the olfactory receptor OR51E2. The composition is internalized into parafoll...
|
|
WO/2020/145790A1 |
The present invention relates to a method for preparing cross-linked hyaluronic acid nanoparticles, comprising irradiating a hyaluronic acid aqueous solution with an electron beam so as to form an intermolecular or intramolecular cross-l...
|
|
WO/2020/146432A1 |
The invention provides methods of depleting CD45+ cells in human patients undergoing chimeric antigen receptor (CAR) immunotherapy in order to promote acceptance of CAR expressing immune cells. Anti-CD45 antibody drug conjugates (ADCs) a...
|
|
WO/2020/142664A1 |
Compositions include a labeling agent featuring a plurality of free labeling units, where each labeling unit includes at least one conjugating group for covalent bonding to a biological molecule, at least one metal chelating group, and a...
|
|
WO/2020/138805A1 |
A composition of the present invention comprises: a radio-labelled liposome encapsulating an Eu-DTPA complex and Victoria-blue BO therein; and a radioactive metal and as such, has high stability and excellent ability to generate reactive...
|
|
WO/2020/131930A1 |
Described herein are methods of treating cancer by inducing favorable effects on tumor microenvironment (e.g., including macrophage polarization, cytokine profile, and/or immunophenotype) via administration of nanoparticles (e.g., silica...
|
|
WO/2020/124237A1 |
A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for...
|
|
WO/2020/130135A1 |
To introduce a halogen into a material such as a protein without using an oxidizing agent, provided is a method for producing a halide, said method being characterized by comprising a step for applying a voltage to a solution that contai...
|
|
WO/2020/122729A1 |
The disclosure is directed to a spherical particle comprising lanthanide hydroxide, a method of preparing the particle, the particle for use in medical applications, a suspension, a composition, a method of obtaining a scanning image, an...
|
|
WO/2020/119205A1 |
A radioactive fluorine-labeled Larotrectinib compound and a preparation method therefor, particularly, an in-vivo imaging agent of a Trk receptor subtype in a refractory solid tumor. Provided are a radioactive fluorine compound 18F-Larot...
|
|
WO/2020/119206A1 |
Disclosed are a radioactive iodine-labelled Larotrectinib compound, a preparation method therefor and the use thereof. The radioactive iodine-labelled Larotrectinib compound includes a radioactive iodine-labelled Larotrectinib compound o...
|
|
WO/2020/123449A1 |
Described herein are compounds and methods of treating or imaging a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutical...
|
|
WO/2020/118426A1 |
The present disclosure relates processes and systems for producing and/or purifying 68Ga from an irradiated substrate of 68Zn. In some embodiments, the process rely on the use two cation- exchange chromatography columns to separate 68Ga ...
|
|
WO/2020/123661A1 |
The present application provides a method of treating a cancer, including administering to a subject in need of cancer treatment a therapeutically effective amount of an mRNA encoding tumor suppressor protein p53 in combination with an a...
|
